BR112014009242A2 - nanossuspensão farmacêutica - Google Patents

nanossuspensão farmacêutica

Info

Publication number
BR112014009242A2
BR112014009242A2 BR112014009242A BR112014009242A BR112014009242A2 BR 112014009242 A2 BR112014009242 A2 BR 112014009242A2 BR 112014009242 A BR112014009242 A BR 112014009242A BR 112014009242 A BR112014009242 A BR 112014009242A BR 112014009242 A2 BR112014009242 A2 BR 112014009242A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical
pharmaceutical suspension
cocrystals
nanosuspension
methods
Prior art date
Application number
BR112014009242A
Other languages
English (en)
Other versions
BR112014009242A8 (pt
Inventor
Vervaet Chris
Paul Remon Jean
Original Assignee
Univ Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Gent filed Critical Univ Gent
Publication of BR112014009242A2 publication Critical patent/BR112014009242A2/pt
Publication of BR112014009242A8 publication Critical patent/BR112014009242A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "nanossuspensão farmacêutica". a presente invenção refere-se em geral a uma suspensão farmacêutica compreendendo cocristais nanodimensionados de pelo menos um ingrediente ativo e pelo menos um ácido dicarboxílico. em particular, refere-se a uma suspensão farmacêutica compreendendo cocristais nanodimensionados de pelo menos um fármaco anti-helmíntico e pelo menos um ácido dicarboxílico. a invenção refere-se ainda a usos, métodos de uso e métodos para produção da suspensão farmacêutica de acordo com esta invenção. 21057254v1
BR112014009242A 2011-10-19 2012-10-18 nanossuspensão farmacêutica BR112014009242A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11185803 2011-10-19
PCT/EP2012/070617 WO2013057169A1 (en) 2011-10-19 2012-10-18 Pharmaceutical nanosuspension

Publications (2)

Publication Number Publication Date
BR112014009242A2 true BR112014009242A2 (pt) 2017-06-13
BR112014009242A8 BR112014009242A8 (pt) 2017-06-20

Family

ID=47088845

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009242A BR112014009242A8 (pt) 2011-10-19 2012-10-18 nanossuspensão farmacêutica

Country Status (13)

Country Link
US (1) US10251866B2 (pt)
EP (1) EP2768485B1 (pt)
AU (1) AU2012324911B2 (pt)
BR (1) BR112014009242A8 (pt)
CA (1) CA2852347C (pt)
DK (1) DK2768485T3 (pt)
ES (1) ES2548706T3 (pt)
HR (1) HRP20151004T1 (pt)
HU (1) HUE027923T2 (pt)
PL (1) PL2768485T3 (pt)
SI (1) SI2768485T1 (pt)
TW (1) TWI580442B (pt)
WO (1) WO2013057169A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140219A1 (ja) * 2015-03-02 2016-09-09 武田薬品工業株式会社 ナノ共結晶を含有する懸濁液または組成物およびこれらの製造方法
EP3170817A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
CN108403646B (zh) * 2018-04-08 2021-04-20 新疆医科大学第一附属医院 阿苯达唑纳米微粉及其制备方法
CN113318079B (zh) * 2021-05-13 2024-01-09 江西博莱大药厂有限公司 一种提高三氯苯达唑颗粒溶出度的方法及其溶出度检测方法
CN114224834B (zh) * 2021-12-24 2022-11-11 沈阳伟嘉生物技术有限公司 一种具有较高生物利用度的阿苯达唑纳米混悬剂及其制备方法
CN117462491A (zh) * 2023-11-26 2024-01-30 江西省保灵动物保健品有限公司 一种阿苯达唑混悬液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5932544A (en) 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
WO2004078163A2 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
ITMI20021074A1 (it) 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
EP1742941A1 (en) * 2004-04-22 2007-01-17 Transform Pharmaceuticals, Inc. Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods
CA2621800A1 (en) 2005-09-06 2007-03-15 Astellas Pharma Inc. Fine particles of poorly soluble drug having enteric base material adsorbed on the surface thereof
NZ599069A (en) * 2006-06-30 2013-10-25 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form
KR20110098012A (ko) * 2007-02-09 2011-08-31 화이자 리미티드 구충제
US20100204204A1 (en) * 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
US20110268775A1 (en) 2009-01-06 2011-11-03 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
WO2011036676A2 (en) 2009-09-23 2011-03-31 Ashwini Nangia Stable cocrystals of temozolomide

Also Published As

Publication number Publication date
CA2852347C (en) 2020-06-30
AU2012324911B2 (en) 2016-09-15
TWI580442B (zh) 2017-05-01
PL2768485T3 (pl) 2015-12-31
WO2013057169A1 (en) 2013-04-25
EP2768485B1 (en) 2015-07-22
TW201323013A (zh) 2013-06-16
ES2548706T3 (es) 2015-10-20
EP2768485A1 (en) 2014-08-27
US10251866B2 (en) 2019-04-09
HRP20151004T1 (hr) 2015-11-20
BR112014009242A8 (pt) 2017-06-20
US20140255498A1 (en) 2014-09-11
SI2768485T1 (sl) 2015-12-31
CA2852347A1 (en) 2013-04-25
AU2012324911A1 (en) 2014-05-22
DK2768485T3 (en) 2015-10-05
HUE027923T2 (en) 2016-11-28

Similar Documents

Publication Publication Date Title
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BR112014001468A2 (pt) compostos de tetra-hidropirido-piridina e tetra-hidropirido-pirimidina e uso dos mesmos como modulares do receptor c5a
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112014009242A8 (pt) nanossuspensão farmacêutica
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CR20120605A (es) Formulación tópica para un inhibidor de jak
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BR112016000092A2 (pt) nanopartículas lipídicas para a cicatrização de feridas
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]